PT3490565T - Derivados de azetidina como moduladores dos recetores de quimiocinas e suas utilizações - Google Patents

Derivados de azetidina como moduladores dos recetores de quimiocinas e suas utilizações

Info

Publication number
PT3490565T
PT3490565T PT178353389T PT17835338T PT3490565T PT 3490565 T PT3490565 T PT 3490565T PT 178353389 T PT178353389 T PT 178353389T PT 17835338 T PT17835338 T PT 17835338T PT 3490565 T PT3490565 T PT 3490565T
Authority
PT
Portugal
Prior art keywords
chemokine receptor
receptor modulators
modulators
chemokine
receptor
Prior art date
Application number
PT178353389T
Other languages
English (en)
Original Assignee
Rapt Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rapt Therapeutics Inc filed Critical Rapt Therapeutics Inc
Publication of PT3490565T publication Critical patent/PT3490565T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT178353389T 2016-07-29 2017-07-28 Derivados de azetidina como moduladores dos recetores de quimiocinas e suas utilizações PT3490565T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662368848P 2016-07-29 2016-07-29
US201662426087P 2016-11-23 2016-11-23

Publications (1)

Publication Number Publication Date
PT3490565T true PT3490565T (pt) 2022-09-06

Family

ID=61016874

Family Applications (1)

Application Number Title Priority Date Filing Date
PT178353389T PT3490565T (pt) 2016-07-29 2017-07-28 Derivados de azetidina como moduladores dos recetores de quimiocinas e suas utilizações

Country Status (20)

Country Link
US (4) US10179787B2 (pt)
EP (1) EP3490565B1 (pt)
JP (1) JP6985388B2 (pt)
KR (1) KR102566924B1 (pt)
CN (1) CN109789146B (pt)
AU (1) AU2017302635B2 (pt)
CA (1) CA3032133A1 (pt)
DK (1) DK3490565T3 (pt)
ES (1) ES2925564T3 (pt)
HU (1) HUE059242T2 (pt)
IL (1) IL264397B2 (pt)
MX (1) MX2019001223A (pt)
NZ (1) NZ750182A (pt)
PL (1) PL3490565T3 (pt)
PT (1) PT3490565T (pt)
RU (1) RU2768827C2 (pt)
SG (1) SG11201900561XA (pt)
TW (1) TWI817929B (pt)
WO (1) WO2018022992A1 (pt)
ZA (1) ZA201900961B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013082490A1 (en) 2011-12-01 2013-06-06 Chemocentryx, Inc. Substituted anilines as ccr(4) antagonists
CA2943075C (en) 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
NZ740616A (en) 2015-09-14 2023-05-26 Infinity Pharmaceuticals Inc Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
KR102566924B1 (ko) 2016-07-29 2023-08-11 랩트 테라퓨틱스, 인크. 케모카인 수용체 조절제 및 이의 용도
RU2020118594A (ru) 2017-11-06 2021-12-09 Рапт Терапьютикс, Инк. Противораковые агенты
BR112020015056A2 (pt) 2018-01-26 2020-12-08 Rapt Therapeutics, Inc. Moduladores de receptor de quimiocina e usos dos mesmos
WO2019178329A1 (en) * 2018-03-16 2019-09-19 The Regents Of The University Of Michigan Compositions and methods for treating graves disease
WO2019228404A1 (zh) * 2018-05-31 2019-12-05 信达生物制药(苏州)有限公司 一种新型磷酸肌醇3-激酶抑制剂及其制备方法和用途
AU2019296173B2 (en) * 2018-06-26 2022-01-06 Kpc Pharmaceuticals, Inc. Benzimidazole derivatives and use thereof as IDH1 inhibitors
MX2021002302A (es) 2018-08-29 2021-04-28 Chemocentryx Inc Terapia de combinacion usando antagonistas de receptor de quimiocina c-c 4 (ccr4) y uno o mas inhibidores de punto de control.
CN109796457B (zh) * 2019-03-28 2020-03-06 苏州国匡医药科技有限公司 一种2-(3-(氮杂环丁烷-3-基)哌啶-1-基)乙基-1-醇的制备方法及其应用
CN112062728A (zh) * 2019-05-25 2020-12-11 上海鑫凯化学科技有限公司 一种3,5-二氯-6-乙基吡嗪甲酰胺的合成方法
MX2022005795A (es) 2019-11-13 2022-06-08 Rapt Therapeutics Inc Formas cristalinas del antagonista del receptor de quimiocinas cc tipo 4 y usos de las mismas.
MX2022007113A (es) * 2019-12-09 2022-07-11 Imago Biosciences Inc Inhibidores de la desmetilasa de la histona especifica de la lisina para el tratamiento de las neoplasias mieloproliferativas.
CN111471025A (zh) * 2020-03-26 2020-07-31 兰州康寓信生物科技有限公司 一种法匹拉韦中间体及法匹拉韦的合成方法
CN111732572B (zh) * 2020-07-31 2020-11-13 苏州国匡医药科技有限公司 一种手性抗肿瘤药物flx475及其中间体的制备方法
CN115466244B (zh) * 2021-06-10 2024-08-02 武汉伯瑞恒医药科技有限公司 趋化因子受体ccr4拮抗剂、其中间体、制备方法、药物组合物和应用
KR20240128987A (ko) 2021-12-30 2024-08-27 바이오메아 퓨전, 인크. Flt3의 억제제로서의 피라진 화합물
WO2023196432A1 (en) * 2022-04-06 2023-10-12 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ES2194181T3 (es) 1996-02-13 2003-11-16 Astrazeneca Ab Derivados de quinazolina como inhibidores de vegf.
DK0885198T3 (da) 1996-03-05 2002-03-25 Astrazeneca Ab 4-Anilinoquinazolinderivater
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
US7030123B2 (en) 2000-05-31 2006-04-18 Astrazeneca Ab Indole derivatives with vascular damaging activity
AU6623201A (en) 2000-07-07 2002-02-05 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
JPWO2003051876A1 (ja) * 2001-12-14 2005-04-28 日本たばこ産業株式会社 ピラゾロピリジン誘導体およびその医薬用途
AU2003252478A1 (en) * 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
WO2005082865A1 (ja) * 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
JP5067364B2 (ja) * 2006-03-24 2012-11-07 アステラス製薬株式会社 アシルアミノピペリジン化合物
JP2010208945A (ja) * 2007-06-01 2010-09-24 Mitsubishi Tanabe Pharma Corp 複素環化合物
KR101048448B1 (ko) * 2008-11-21 2011-07-11 한국화학연구원 신규 피라졸로[4,3-ｂ]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
JP2010126496A (ja) * 2008-11-28 2010-06-10 Mitsubishi Tanabe Pharma Corp 複素環化合物
CN102388039B (zh) * 2009-02-26 2015-07-15 葛兰素集团有限公司 用作ccr4受体拮抗剂的吡唑衍生物
CN102666545B (zh) * 2009-10-20 2016-04-06 塞尔卓姆有限公司 作为jak抑制剂的杂环吡唑并嘧啶类似物
JP2013525370A (ja) * 2010-04-22 2013-06-20 ヤンセン ファーマシューティカ エヌ．ベー． ケトヘキソキナーゼ阻害剤として有用なインダゾール化合物
WO2012022681A2 (en) * 2010-08-20 2012-02-23 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors
WO2013082490A1 (en) 2011-12-01 2013-06-06 Chemocentryx, Inc. Substituted anilines as ccr(4) antagonists
US8685959B2 (en) 2011-12-01 2014-04-01 Chemocentryx, Inc. Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists
WO2014026327A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
WO2016021742A1 (en) * 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
WO2016192083A1 (en) * 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
KR102566924B1 (ko) 2016-07-29 2023-08-11 랩트 테라퓨틱스, 인크. 케모카인 수용체 조절제 및 이의 용도

Also Published As

Publication number Publication date
KR102566924B1 (ko) 2023-08-11
EP3490565A1 (en) 2019-06-05
PL3490565T3 (pl) 2022-09-26
US10604526B2 (en) 2020-03-31
BR112019001732A2 (pt) 2019-05-07
CA3032133A1 (en) 2018-02-01
JP6985388B2 (ja) 2021-12-22
WO2018022992A1 (en) 2018-02-01
EP3490565A4 (en) 2019-12-25
RU2019105534A3 (pt) 2020-10-20
IL264397A (en) 2019-02-28
US20190152978A1 (en) 2019-05-23
NZ750182A (en) 2023-03-31
RU2019105534A (ru) 2020-08-28
TW201808958A (zh) 2018-03-16
HUE059242T2 (hu) 2022-11-28
DK3490565T3 (da) 2022-07-11
SG11201900561XA (en) 2019-02-27
AU2017302635A1 (en) 2019-02-14
CN109789146A (zh) 2019-05-21
ZA201900961B (en) 2020-05-27
TWI817929B (zh) 2023-10-11
AU2017302635B2 (en) 2021-09-16
MX2019001223A (es) 2019-11-11
JP2019525962A (ja) 2019-09-12
IL264397B2 (en) 2024-04-01
US20180072740A1 (en) 2018-03-15
KR20190041471A (ko) 2019-04-22
RU2768827C2 (ru) 2022-03-24
US20200239480A1 (en) 2020-07-30
CN109789146B (zh) 2023-04-18
EP3490565B1 (en) 2022-06-08
ES2925564T3 (es) 2022-10-18
US20240199620A1 (en) 2024-06-20
IL264397B1 (en) 2023-12-01
US10179787B2 (en) 2019-01-15

Similar Documents

Publication Publication Date Title
ZA201900961B (en) Chemokine receptor modulators and uses thereof
HK1247199A1 (zh) 雌激素受體調節劑及其用途
IL276295A (en) Modulators of chemokine receptors and their uses
ZA201807731B (en) Spiro-lactam nmda receptor modulators and uses thereof
IL247847B (en) ror gamma modulator and their use
IL264514A (en) Spiro-lactam modulates and uses of the nmda receptor
IL264488A (en) Spiro-lactam nmda receptor modulators and uses thereof
HK1255160A1 (zh) 取代的4-氮雜吲哚以及它們作為glun2b受體調節劑的用途
IL286107A (en) Spiro-lactam nmda receptor modulators and uses thereof
EP3490994C0 (en) SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND THEIR USE
HK1258886A1 (zh) T細胞受體及其用途
PT3166636T (pt) Moduladores de psgl-1 e utilizações dos mesmos
PT3386591T (pt) Moduladores de recetores nmda heteroaromáticos e suas utilizações
HK1245259A1 (zh) 作為nmda受體調節劑的吡啶並嘧啶酮類及它們的用途
PL3347376T3 (pl) Nowy receptor IGFR-podobny i jego zastosowania
ZA201905511B (en) Rorgamma modulators and uses thereof
ZA201905513B (en) Rorgamma modulators and uses thereof
HK1253294A1 (zh) 阿片受體調節劑及其用途
ZA201606656B (en) Ror-gamma modulators and uses thereof